UniQure: Controversy Abounds As Stock Price Halves On FDA News
Source: SeekingAlpha
2025-11-04 11:00:23 ET
Investment Overview - UniQure's Recent Gains On Huntington's Disease Data Undermined By FDA Decision
Read the full article on Seeking Alpha
For further details see:
UniQure: Controversy Abounds As Stock Price Halves On FDA News
uniQure N.V.
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
